Summary

The spatial genomics & transcriptomics product market is expected to reach USD 995.7 million in 2029 from USD 554.5 million in 2024, at a CAGR of 12.4% during the forecast period.
The spatial genomics and transcriptomics market is expanding under the influence of factors like new product introduction and rising acceptance of spatial genomics and transcriptomics in medication discovery and development. Nevertheless, expensive initial capital inputs and technical complexity and knowledge gap create various difficulties for the industry.
"The product segment accounted for the largest share by offering segment in the spatial genomics & transcriptomics market in 2023".
Products and services divide the spatial genomics & transcriptomics market. In 2023 the product segment held the biggest share. The growing demand for high-resolution spatial gene and protein expression data in research helps to explain the expansion of this area. The main forces behind the market expansion are the expanding uses of consumables and spatial genomics and transcriptomics in drug research and development as well as biomarketer identification. Key element driving development in this market segment is increased investments by market participants in creating various software especially for spatial analysis and introduction of new goods.
"The spatial transcriptomics technique held the highest market share of the spatial genomics and transcriptomics market by technique in 2023".
Techniques divide the spatial genomics and transcriptomics market into spatial transcriptomics and spatial genomics segments. Driven by growing acceptance of in situ sequencing technologies and more general applications in disease research, the segment of spatial transcriptomics held the biggest share of spatial genomics & transcriptomics market in 2023. Using spatial transcriptomics, one may map gene expression inside the spatial context of a tissue. Combining histology and molecular data reveals how genes are expressed in certain tissue country or region, so providing understanding of cellular organization, function, and disease progression.
"The Asia Pacific region is growing at the highest CAGR in the spatial genomics & transcriptomics market from 2024 to 2029."
The Asia Pacific is estimated to be the fastest-growing segment of the market owing to the a
increasing government efforts to rising healthcare needs, growing government investment in
biotechnology, growing demand of precision medicine, rising healthcare expenditure, growing
R&D expansion in key markets such as India, China, and Japan, and the favorable regulatory
environment in the region. However, North America held the largest share of spatial genomics & transcriptomics market in 2023.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 60% and Demand Side 40%
• By Designation: Managers - 45% CXOs and Director-level - 30%, and Executives - 25%,
• By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, and Middle East -5%.

List of Companies Profiled in the Report:
• NanoString Technologies, Inc. (Bruker Spatial Biology, Inc.) (US)
• 10x Genomics (US)
• Bio-Rad Laboratories, Inc. (US)
• Illumina, Inc. (US)
• Bio-Techne (US)
• Seven Bridges Genomics (US)
• Rarecyte, Inc. (US)
• Standard BioTools (US)
• Revvity (US)
• Akoya Biosciences, Inc. (US)
• Natera, Inc. (US)
• VisioPharm A/S (Switzerland)
• Danaher Corporation (US)
• Veracyte, Inc. (US)
• Biomarker Technologies (BMKGENE) (China)
• Macrogen, Inc. (South Korea)
• Miltenyi Biotec (Germany)
• Sony Biotechnology Inc. (US)
• Vizgen Inc. (US)
• BioSpyder, Inc. (US)
• Ionpath, Inc. (US)
• S2 Genomics, Inc. (US)
• Ultivue, Inc. (US)
• Admera Health (US)
• Lunaphore Technologies SA (US)
• Visikol, Inc. (US)
• Rebus Biosystems, Inc. (US)
• Singular Genomics Systems, Inc. (US)
• Cantata Bio (US)
• Nucleai, Inc. (Israel)

Research Coverage:
This research report categorizes the spatial genomics & transcriptomics market by offering (products and services), by technique (spatial transcriptomics and spatial genomics), by type (service) (sample preparation services, sequencing & analytical services, and data visualization & analysis services), by application (translational research and drug discovery & development), by end user (product) (pharmaceutical & biotechnology companies, academic & research institutes, CROs & CDMOs, and clinical diagnostic laboratories), by end user (service) (pharmaceutical & biotechnology companies, academic & research institutes, and other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the spatial genomics & transcriptomics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product & service portfolio, key strategies such as product & service launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the spatial genomics & transcriptomics market. Competitive analysis of top players and upcoming startups in the spatial genomics & transcriptomics market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall spatial genomics & transcriptomics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Increasing adoption of spatial genomics and transcriptomics in drug discovery and development, Introduction of novel products, Increasing pharmaceutical R&D investments and public-private funding), restraints (High initial capital investments and maintenance costs, Technical complexity and expertise gap), opportunities (Increasing use of spatial omics for biomarker identification, Increasing demand for precision medicines and targeted drug development), and challenges (Dearth of skilled professionals) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched product/services of the spatial genomics & transcriptomics market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the spatial genomics & transcriptomics market
• Competitive Assessment: NanoString Technologies, Inc. (Bruker Spatial Biology, Inc.) (US), 10x Genomics (US), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), Bio-Techne (US), Seven Bridges Genomics (US), Rarecyte, Inc. (US), Standard BioTools (US), Revvity (US), Akoya Biosciences, Inc. (US), Natera, Inc. (US), VisioPharm A/S (Switzerland), Danaher Corporation (US), Veracyte, Inc. (US), Biomarker Technologies (BMKGENE) (China), Macrogen, Inc. (South Korea), Miltenyi Biotec (Germany), Sony Biotechnology Inc. (US), Vizgen Inc. (US), BioSpyder, Inc. (US), Ionpath, Inc. (US), S2 Genomics, Inc. (US), Ultivue, Inc. (US), Admera Health (US), Lunaphore Technologies SA (US), Visikol, Inc. (US), Rebus Biosystems, Inc. (US), Singular Genomics Systems, Inc. (US), Cantata Bio (US), and Nucleai, Inc. (Israel).

ページTOPに戻る

Table of Contents

1 INTRODUCTION 41
1.1 STUDY OBJECTIVES 41
1.2 MARKET DEFINITION 41
1.3 INCLUSIONS & EXCLUSIONS 42
1.4 STUDY SCOPE 42
1.4.1 SEGMENTS AND REGIONS CONSIDERED 43
1.4.2 YEARS CONSIDERED 44
1.4.3 CURRENCY CONSIDERED 44
1.5 STAKEHOLDERS 44
1.6 SUMMARY OF CHANGES 45
1.6.1 IMPACT OF AI/GEN AI 45
2 RESEARCH METHODOLOGY 46
2.1 RESEARCH DATA 46
2.1.1 SECONDARY DATA 47
2.1.1.1 Objectives of secondary research 47
2.1.2 PRIMARY DATA 47
2.1.2.1 Breakdown of primaries 48
2.1.2.2 Objectives of primary research 48
2.2 MARKET SIZE ESTIMATION 49
2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH) 50
2.2.1.1 Insights from primary sources 53
2.2.2 SEGMENTAL MARKET ESTIMATION: TOP-DOWN APPROACH (PRODUCT) 53
2.3 GROWTH RATE PROJECTIONS 54
2.4 DATA TRIANGULATION 57
2.5 STUDY ASSUMPTIONS 58
2.6 RESEARCH LIMITATIONS 59
2.7 RISK ANALYSIS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 65
4.1 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET OVERVIEW 65
4.2 ASIA PACIFIC: SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET SHARE, BY TECHNIQUE AND COUNTRY (2023) 66
4.3 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 67
 
4.4 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET SHARE,
BY END USER (2023) 68
4.5 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET SHARE,
BY END USER (2023) 68
5 MARKET OVERVIEW 69
5.1 INTRODUCTION 69
5.2 MARKET DYNAMICS 69
5.2.1 DRIVERS 70
5.2.1.1 Increasing adoption of spatial genomics and transcriptomics in drug discovery and development 70
5.2.1.2 Introduction of novel products 71
5.2.1.3 Increasing pharmaceutical R&D investments and public-private funding 71
5.2.2 RESTRAINTS 72
5.2.2.1 High initial capital investments and maintenance costs 72
5.2.2.2 Technical complexity and expertise gap 72
5.2.3 OPPORTUNITIES 73
5.2.3.1 Increasing use of spatial omics for biomarker identification 73
5.2.3.2 Growing demand for precision medicines and targeted drug development 73
5.2.4 CHALLENGES 74
5.2.4.1 Dearth of skilled professionals 74
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 74
5.4 PRICING ANALYSIS 75
5.4.1 AVERAGE SELLING PRICE TREND OF INSTRUMENTS,
BY KEY PLAYER, 2021–2023 76
5.4.2 AVERAGE SELLING PRICE TREND OF CONSUMABLES,
BY KEY PLAYER, 2021–2023 77
5.4.3 AVERAGE SELLING PRICE OF KEY PRODUCTS, BY REGION, 2021–2023 78
5.5 SUPPLY CHAIN ANALYSIS 80
5.6 VALUE CHAIN ANALYSIS 82
5.7 ECOSYSTEM ANALYSIS 83
5.8 TECHNOLOGY ANALYSIS 85
5.8.1 KEY TECHNOLOGIES 85
5.8.1.1 In-situ sequencing 85
5.8.1.2 In-situ hybridization 86
5.8.1.3 Single-cell RNA sequencing 86
5.8.2 COMPLEMENTARY TECHNOLOGIES 86
5.8.2.1 Multi-isotope imaging mass spectrometry 86
5.8.2.2 Spatial heatmap 86
5.8.2.3 Differential gene expression analysis 86
 
5.8.3 ADJACENT TECHNOLOGIES 87
5.8.3.1 Multi-omics 87
5.8.3.2 Metabolomics 87
5.8.3.3 Single-cell analysis 87
5.9 PATENT ANALYSIS 88
5.10 KEY CONFERENCES & EVENTS, 2025–2026 90
5.11 REGULATORY LANDSCAPE 91
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 91
5.11.2 REGULATORY FRAMEWORK 93
5.12 PORTER’S FIVE FORCES ANALYSIS 94
5.12.1 THREAT OF NEW ENTRANTS 96
5.12.2 THREAT OF SUBSTITUTES 96
5.12.3 BARGAINING POWER OF BUYERS 96
5.12.4 BARGAINING POWER OF SUPPLIERS 96
5.12.5 INTENSITY OF COMPETITIVE RIVALRY 97
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 97
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 97
5.13.2 KEY BUYING CRITERIA, BY END USER (PRODUCT) 98
5.14 TRADE ANALYSIS 99
5.14.1 IMPORT DATA FOR HS CODE 902790 100
5.14.2 EXPORT DATA FOR HS CODE 902790 100
5.15 INVESTMENT & FUNDING SCENARIO 101
5.16 IMPACT OF AI/GEN AI ON SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET 102
6 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY OFFERING 103
6.1 INTRODUCTION 104
6.2 PRODUCTS 104
6.2.1 INSTRUMENTS & SOFTWARE 107
6.2.1.1 Instruments & software to facilitate disease research by enabling detailed spatial mapping and multi-omic analyses 107
6.2.2 CONSUMABLES 110
6.2.2.1 Better reproducible and high-quality data collection to advance spatial genomics research in oncology and precision medicine 110
6.3 SERVICES 113
6.3.1 INCREASING DEMAND FOR HIGH-QUALITY SPATIAL DATA IN PRECISION MEDICINE TO AUGMENT MARKET GROWTH 113
7 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET,
BY TECHNIQUE 117
7.1 INTRODUCTION 118
7.2 SPATIAL TRANSCRIPTOMICS 118
7.2.1 IMMUNOHISTOCHEMISTRY 121
7.2.1.1 Increasing applications in biomarker discovery and cellular interactions within tissue architecture to drive segment 121
7.2.2 IMMUNOFLUORESCENCE 124
7.2.2.1 Advanced profiling immune-tumor microenvironments for cancer diagnosis and prognosis to propel segment growth 124
7.2.3 MICROSCOPY-BASED RNA IMAGING 127
7.2.3.1 Better insights into molecular communication within tissue architecture to augment segment growth 127
7.2.4 IN-SITU HYBRIDIZATION 130
7.2.4.1 High-throughput and 3D spatial gene expression analysis in cancer research and developmental biology to drive segment 130
7.2.5 LASER CAPTURE MICRODISSECTION 132
7.2.5.1 Analysis of gene expression data from defined cellular populations to facilitate spatial mapping within tissue sections 132
7.2.6 RNA SEQUENCING 135
7.2.6.1 In-situ RNA sequencing 138
7.2.6.1.1 Integration of ISS with bioinformatics toolkits for data analysis to facilitate interpretation of complex datasets 138
7.2.6.2 Single-cell RNA (SC-RNA) sequencing 140
7.2.6.2.1 Increasing commercial availability of scRNA-seq platforms and advancements in bioinformatics tools to drive segment 140
7.2.6.3 Other RNA sequencing 143
7.2.7 OTHER SPATIAL TRANSCRIPTOMIC TECHNIQUES 145
7.3 SPATIAL GENOMICS 148
7.3.1 IN-SITU HYBRIDIZATION 151
7.3.1.1 Demand for high-specificity detection platforms to fuel market growth 151
7.3.2 LASER CAPTURE MICRODISSECTION 154
7.3.2.1 Detailed insights into cellular mechanisms and molecular profiles within heterogeneous tissue samples to drive segment 154
7.3.3 GENOMIC SEQUENCING 156
7.3.3.1 Microdissection-based sequencing 159
7.3.3.1.1 Increased demand for precision medicines to boost segment growth 159
7.3.3.2 Chromatin accessibility sequencing 162
7.3.3.2.1 Need for insights into gene regulation and epigenetic modifications to aid segment growth 162
7.3.3.3 Other genomic sequencing 164
7.3.4 OTHER SPATIAL GENOMIC TECHNIQUES 167
8 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET, BY TYPE 170
8.1 INTRODUCTION 171
8.2 SAMPLE PREPARATION SERVICES 171
8.2.1 NEED FOR ACCURATE SPATIAL ANALYSIS OF GENE EXPRESSION WITHIN TISSUE SAMPLES TO SPUR MARKET GROWTH 171
 
8.3 SEQUENCING & ANALYTICAL SERVICES 174
8.3.1 SEQUENCING & ANALYTICAL SERVICES TO UTILIZE ADVANCED TECHNOLOGIES FOR SEQUENCING AND BIOINFORMATICS ANALYSIS 174
8.4 DATA VISUALIZATION & ANALYSIS SERVICES 177
8.4.1 INCREASED DEMAND FOR ADVANCED TOOLS FOR COMPLEX SPATIAL GENOMICS DATA INTERPRETATION TO SUPPORT MARKET GROWTH 177
9 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY APPLICATION 180
9.1 INTRODUCTION 181
9.2 TRANSLATIONAL RESEARCH 181
9.2.1 CANCER 184
9.2.1.1 Spatial genomics and transcriptomics to map precise locations of DNA and RNA within tumor tissues in cancer research 184
9.2.2 IMMUNOLOGY 187
9.2.2.1 Need for better understanding of immune cell interactions and tissue-specific immune responses to propel segment growth 187
9.2.3 NEUROSCIENCE 189
9.2.3.1 Increased focus on mapping cellular diversity for analyzing brain function and dysfunction to aid market growth 189
9.2.4 INFECTIOUS DISEASES 192
9.2.4.1 Need for enhanced understanding of pathogen-host interactions at tissue level to drive adoption 192
9.2.5 OTHER DISEASES 195
9.3 DRUG DISCOVERY & DEVELOPMENT 197
9.3.1 RISING USE OF RNA-SEQ IN DISEASE MANAGEMENT DRUG DISCOVERY TO DRIVE MARKET 197
10 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET,
BY END USER 201
10.1 INTRODUCTION 202
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 202
10.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO TRANSFORM DISEASE RESEARCH AND STREAMLINE DRUG TARGET VALIDATION 202
10.3 ACADEMIC & RESEARCH INSTITUTES 205
10.3.1 FOCUS ON FOUNDATIONAL DISCOVERIES AND CELLULAR INSIGHTS ABOUT COMPLEX BIOLOGICAL SYSTEMS TO AID MARKET GROWTH 205
10.4 CROS & CDMOS 208
10.4.1 GROWING DEMAND FOR PRECISE SPATIAL MOLECULAR INSIGHTS TO PROPEL MARKET GROWTH 208
10.5 CLINICAL DIAGNOSTIC LABORATRIES 211
10.5.1 IMPROVED DIAGNOSTIC ACCURACY IN PATHOGEN DETECTION AND GENOMIC ANALYSIS TO AID MARKET GROWTH 211
 
11 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET, BY END USER 215
11.1 INTRODUCTION 216
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 216
11.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO OPTIMIZE BIOMARKER DEVELOPMENT AND IMPROVE CLINICAL TRIAL DESIGN 216
11.3 ACADEMIC & RESEARCH INSTITUTES 219
11.3.1 NEED FOR TOOLS FOR MAPPING CELLULAR ENVIRONMENTS AND STUDYING DISEASE MECHANISMS TO PROPEL MARKET GROWTH 219
11.4 OTHER END USERS 222
12 SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET, BY REGION 225
12.1 INTRODUCTION 226
12.2 NORTH AMERICA 227
12.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK 232
12.2.2 US 233
12.2.2.1 US to dominate North American spatial genomics & transcriptomics market during forecast period 233
12.2.3 CANADA 238
12.2.3.1 Favorable government initiatives and high incidence of infectious diseases to support market growth 238
12.3 EUROPE 242
12.3.1 EUROPE: MACROECONOMIC OUTLOOK 248
12.3.2 GERMANY 249
12.3.2.1 Advanced genomics research and presence of several key companies to spur market growth 249
12.3.3 UK 253
12.3.3.1 Increasing government funding and rising demand for new diagnostic biomarkers to aid market growth 253
12.3.4 FRANCE 258
12.3.4.1 Increasing investments in life science R&D and rising number of biotech companies to propel market growth 258
12.3.5 ITALY 262
12.3.5.1 Increasing focus on neuroscience and rare disease research to augment market growth 262
12.3.6 SPAIN 267
12.3.6.1 Focus on advanced cancer research and increased need for personalized medicines to propel market growth 267
12.3.7 REST OF EUROPE 271
12.4 ASIA PACIFIC 276
12.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK 283
12.4.2 CHINA 284
12.4.2.1 Increasing R&D spending by government and biopharma companies to propel market growth 284
 
12.4.3 JAPAN 289
12.4.3.1 Favorable government policies and high R&D funding to boost market growth 289
12.4.4 INDIA 293
12.4.4.1 Increasing collaborations between hospitals and diagnostics centers to boost market growth 293
12.4.5 SOUTH KOREA 298
12.4.5.1 Increased research on advanced precision medicines and well-established biotechnology infrastructure to aid market growth 298
12.4.6 AUSTRALIA 302
12.4.6.1 Strategic focus on advancing cancer research and precision oncology to boost market growth 302
12.4.7 REST OF ASIA PACIFIC 307
12.5 LATIN AMERICA 312
12.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK 317
12.5.2 BRAZIL 318
12.5.2.1 Increasing adoption of biomarkers for drug discovery & development to drive market 318
12.5.3 MEXICO 322
12.5.3.1 Favorable funding scenario in biotechnology sector and high funding in biomanufacturing to augment market growth 322
12.5.4 REST OF LATIN AMERICA 326
12.6 MIDDLE EAST 331
12.6.1 LOWER R&D INVESTMENTS AND WEAK INFRASTRUCTURAL DEVELOPMENTS TO HINDER MARKET GROWTH 331
12.6.2 MIDDLE EAST: MACROECONOMIC OUTLOOK 335
12.7 AFRICA 336
12.7.1 INCREASING FUNDING AND PARTNERSHIPS IN RESEARCH SECTOR TO SUPPORT GROWTH OF BIOTECHNOLOGY INDUSTRY 336
12.7.2 AFRICA: MACROECONOMIC OUTLOOK 341
13 COMPETITIVE LANDSCAPE 343
13.1 INTRODUCTION 343
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 343
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SPATIAL GENOMICS & TRANSCRIPTOMICS MARKET 344
13.3 REVENUE ANALYSIS, 2019−2023 348
13.4 MARKET SHARE ANALYSIS, 2023 349
13.4.1 SPATIAL GENOMICS & TRANSCRIPTOMICS PRODUCTS MARKET 349
13.4.2 SPATIAL GENOMICS & TRANSCRIPTOMICS SERVICES MARKET 351
13.4.3 RANKING OF KEY MARKET PLAYERS 351
13.5 COMPANY VALUATION & FINANCIAL METRICS 352
13.5.1 COMPANY VALUATION 352
13.5.2 FINANCIAL METRICS 352
13.6 BRAND/PRODUCT COMPARISON 353
13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 355
13.7.1 STARS 355
13.7.2 EMERGING LEADERS 355
13.7.3 PERVASIVE PLAYERS 355
13.7.4 PARTICIPANTS 355
13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 357
13.7.5.1 Company footprint 357
13.7.5.2 Region footprint 358
13.7.5.3 Offering footprint 359
13.7.5.4 Technique footprint 360
13.7.5.5 Application footprint 361
13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 362
13.8.1 PROGRESSIVE COMPANIES 362
13.8.2 RESPONSIVE COMPANIES 362
13.8.3 DYNAMIC COMPANIES 362
13.8.4 STARTING BLOCKS 362
13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 364
13.8.5.1 Detailed list of key startups/SMEs 364
13.8.5.2 Competitive benchmarking of key startups/SMEs 365
13.9 COMPETITIVE SCENARIO 366
13.9.1 PRODUCT LAUNCHES 366
13.9.2 DEALS 367
13.9.3 EXPANSIONS 368
14 COMPANY PROFILES 369
14.1 KEY PLAYERS 369
14.1.1 10X GENOMICS 369
14.1.1.1 Business overview 369
14.1.1.2 Products/Services/Solutions offered 371
14.1.1.3 Recent developments 372
14.1.1.3.1 Product launches 372
14.1.1.3.2 Deals 373
14.1.1.3.3 Expansions 373
14.1.1.4 MnM view 374
14.1.1.4.1 Key strengths 374
14.1.1.4.2 Strategic choices 374
14.1.1.4.3 Weaknesses and competitive threats 374
14.1.2 BIO-TECHNE 375
14.1.2.1 Business overview 375
14.1.2.2 Products/Services/Solutions offered 376
14.1.2.3 Recent developments 378
14.1.2.3.1 Product launches 378
14.1.2.3.2 Deals 379
14.1.2.3.3 Expansions 379
14.1.2.4 MnM view 380
14.1.2.4.1 Key strengths 380
14.1.2.4.2 Strategic choices 380
14.1.2.4.3 Weaknesses and competitive threats 380
14.1.3 NANOSTRING TECHNOLOGIES, INC. (BRUKER SPATIAL BIOLOGY, INC.) 381
14.1.3.1 Business overview 381
14.1.3.2 Products/Services/Solutions offered 383
14.1.3.3 Recent developments 384
14.1.3.3.1 Product launches 384
14.1.3.3.2 Deals 385
14.1.3.4 MnM view 386
14.1.3.4.1 Key strengths 386
14.1.3.4.2 Strategic choices 386
14.1.3.4.3 Weaknesses and competitive threats 386
14.1.4 STANDARD BIOTOOLS 387
14.1.4.1 Business overview 387
14.1.4.2 Products/Services/Solutions offered 389
14.1.4.3 Recent developments 391
14.1.4.3.1 Product launches 391
14.1.4.3.2 Deals 391
14.1.4.4 MnM view 392
14.1.4.4.1 Key strengths 392
14.1.4.4.2 Strategic choices 392
14.1.4.4.3 Weaknesses and competitive threats 392
14.1.5 ILLUMINA, INC. 393
14.1.5.1 Business overview 393
14.1.5.2 Products/Services/Solutions offered 395
14.1.5.3 Recent developments 396
14.1.5.3.1 Product launches 396
14.1.5.3.2 Deals 396
14.1.5.4 MnM view 397
14.1.5.4.1 Key strengths 397
14.1.5.4.2 Strategic choices 397
14.1.5.4.3 Weaknesses and competitive threats 397
14.1.6 BIO-RAD LABORATORIES, INC. 398
14.1.6.1 Business overview 398
14.1.6.2 Products/Services/Solutions offered 399
14.1.6.3 Recent developments 400
14.1.6.3.1 Product launches 400
14.1.6.3.2 Deals 400
14.1.7 AKOYA BIOSCIENCES, INC. 401
14.1.7.1 Business overview 401
14.1.7.2 Products/Services/Solutions offered 402
14.1.7.3 Recent developments 402
14.1.7.3.1 Product launches 402
14.1.7.3.2 Deals 403
14.1.7.3.3 Expansions 404
14.1.8 VISIOPHARM A/S 405
14.1.8.1 Business overview 405
14.1.8.2 Products/Services/Solutions offered 405
14.1.8.3 Recent developments 406
14.1.8.3.1 Product launches 406
14.1.8.3.2 Deals 406
14.1.9 DANAHER CORPORATION 407
14.1.9.1 Business overview 407
14.1.9.2 Products/Services/Solutions offered 409
14.1.9.3 Recent developments 409
14.1.9.3.1 Deals 409
14.1.10 SEVEN BRIDGES GENOMICS 410
14.1.10.1 Business overview 410
14.1.10.2 Products/Services/Solutions offered 410
14.1.10.3 Recent developments 411
14.1.10.3.1 Deals 411
14.1.11 REVVITY 412
14.1.11.1 Business overview 412
14.1.11.2 Products/Services/Solutions offered 414
14.1.11.3 Recent developments 414
14.1.11.3.1 Product launches & approvals 414
14.1.11.3.2 Deals 415
14.1.12 VIZGEN INC. 416
14.1.12.1 Business overview 416
14.1.12.2 Products/Services/Solutions offered 416
14.1.12.3 Recent developments 417
14.1.12.3.1 Product launches 417
14.1.12.3.2 Deals 418
14.1.13 VERACYTE, INC. 419
14.1.13.1 Business overview 419
14.1.13.2 Products/Services/Solutions offered 419
 
14.1.14 NATERA, INC. 420
14.1.14.1 Business overview 420
14.1.14.2 Products/Services/Solutions offered 422
14.1.14.3 Recent developments 422
14.1.14.3.1 Product launches 422
14.1.14.3.2 Expansions 423
14.1.15 MACROGEN INC. 424
14.1.15.1 Business overview 424
14.1.15.2 Products/Services/Solutions offered 425
14.1.15.3 Recent developments 425
14.1.15.3.1 Deals 425
14.1.16 MILTENYI BIOTEC 426
14.1.16.1 Business overview 426
14.1.16.2 Products/Services/Solutions offered 426
14.1.16.3 Recent developments 427
14.1.16.3.1 Deals 427
14.2 OTHER PLAYERS 428
14.2.1 BIOMARKER TECHNOLOGIES (BMKGENE) 428
14.2.2 ULTIVUE, INC. 429
14.2.3 RARECYTE, INC. 430
14.2.4 S2 GENOMICS, INC. 431
14.2.5 ADMERA HEALTH 432
14.2.6 SONY BIOTECHNOLOGY INC. 433
14.2.7 CANTATA BIO 434
14.2.8 NUCLEAI, INC. 435
14.2.9 VISIKOL, INC. 436
14.2.10 IONPATH, INC. 437
14.2.11 BIOSPYDER, INC. 438
14.2.12 SINGULAR GENOMICS SYSTEMS, INC. 439
14.2.13 LUNAPHORE TECHNOLOGIES SA 440
14.2.14 REBUS BIOSYSTEMS, INC. 441
15 APPENDIX 442
15.1 DISCUSSION GUIDE 442
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 446
15.3 CUSTOMIZATION OPTIONS 448
15.4 RELATED REPORTS 448
15.5 AUTHOR DETAILS 449